Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2070]

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF...

Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer...

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

More ovarian cancer patients benefit from maintenance combined targeted therapy

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Comment: Immunotherapy combination for advanced NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Comment: Front-line osimertinib significantly lengthens overall survival in...

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

PLEIADES: Daratumumab combinations for multiple myeloma

Dr Ajai Chari - Mount Sinai, New York City, USA

PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Appraising an NTRK testing algorithm: When, what, how

Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca

Appraising an NTRK testing algorithm: When, what, how ( Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca )

More from ecancer